Hans Fredrik Mattsson

Hans Fredrik Mattsson currently works at Celemi International AB, as Chairman, Dipylon Medical AB, as Director, Investment AB Bure, as Director, and Bure Growth AB, as Director.
Mr. Mattsson also formerly worked at Vittra Utbildning AB, as Chief Executive Officer, Anew Learning AB, as Chief Executive Officer, Xvivo Perfusion AB, as Chairman from 2012 to 2018, BioLamina AB, as Chairman, Bure Equity AB, as Investment Director from 2009 to 2018, Vitrolife AB, as Independent Director from 2007 to 2018, Mercuri International Group AB, as Director, MedCap AB, as Director, Bure Equity, as Investment Director from 2010 to 2018, Energo-Retea AB, as Director, Celemiab Group AB, as Director, Theducation AB, as Director, Life Genomics AB, as Director, Devyser Diagnostics AB, as Independent Director, Skanditek Industriförvaltning AB, as Principal, Gambro Renal Products, Inc., as Vice President-Homecare, and McKinsey & Co. Service AB, as Management Consultant.